News
PLX
1.230
+4.24%
0.050
Weekly Report: what happened at PLX last week (0513-0517)?
Weekly Report · 5d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Akanda (NASDAQ:AKAN) shares rose to $ during Friday's pre-market session. Scorpius Holdings (AMEX:SCorpius) and Doximity (NYSE:DOCS) shares increased by during the session. Reneo Pharmaceuticals and 180 Life Sciences were losers in the pre- market session.
Benzinga · 05/17 12:07
Weekly Report: what happened at PLX last week (0506-0510)?
Weekly Report · 05/13 11:29
Protalix Biotherapeutics, Inc. Form 10-Q for the Quarterly Period Ended March 31, 2024
Press release · 05/10 23:19
PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Misses Revenue for Q1 2024
Protalix BioTherapeutics reported earnings per share of -6 cents for the first quarter of 2024. The company reported revenue of $3.75 million. This was 59.26% worse than the analyst estimate for revenue in the same period. Protalix also reported results for the fourth quarter of 2015.
Investorplace · 05/10 15:54
Novavax, Macrogenics, Biofrontera among healthcare movers
Healthcare On the Move: Novavax, Macrogenics, Biofrontera among healthcare movers. S&P 500 Health Care Sector +0.12% to 1670.59. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 05/10 14:00
NOTV, BFRI and CPOP among pre-market losers
NotV, BFRI and CPOP among pre-market losers. Macrogenics (MGNX) -68% after Q1 earnings release. Microvision (MVIS) -28% after quarterly earnings release; Progyny (PGNY) -26%. Allakos (ALLK) -5%.
Seeking Alpha · 05/10 12:30
12 Health Care Stocks Moving In Friday's Pre-Market Session
Aethlon Medical (NASDAQ:AEMD) stock moved upwards by 129.0% to $2.7 during Friday's pre-market session. Novavax shares rose 119.23% and Natera shares rose 20.31% during the same time period. Sensus Healthcare and XTL Biopharmaceuticals also moved upwards. Losers Macrogenics and Progyny stock declined by 67.0%.
Benzinga · 05/10 12:07
Options Volatility and Implied Earnings Moves Today, May 10, 2024
TipRanks · 05/10 11:05
Protalix BioTherapeutics Inc. Q1 Loss Increases, Misses Estimates
NASDAQ · 05/10 10:55
Protalix BioTherapeutics GAAP EPS of -$0.06 misses by $0.04, revenue of $3.75M
Protalix BioTherapeutics GAAP EPS of -$0.06 misses by $0.04, revenue of $3.75M (-60.9% Y/Y) The company recorded revenues from selling goods for the three months ended March 31, 2024.
Seeking Alpha · 05/10 10:54
Protalix BioTherapeutics Q1 Earnings Preview
Protalix BioTherapeutics, Inc. Is scheduled to announce Q1 earnings results on Friday, May 10th. The consensus EPS Estimate is -$0.02 and the consensus revenue estimate is $9.2M. PLX has beaten revenue estimates 100% of the time in the last year.
Seeking Alpha · 05/09 16:27
Weekly Report: what happened at PLX last week (0429-0503)?
Weekly Report · 05/06 11:36
Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024
Company to host conference call and webcast at 8:30 a.m. EDT on May 10, 2024. Protalix BioTherapeutics, Inc. Will release its financial results for the quarter ended March 31, 2024 and provide a business and clinical update. The company is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins.
PR Newswire · 05/03 10:50
Weekly Report: what happened at PLX last week (0422-0426)?
Weekly Report · 04/29 11:43
Weekly Report: what happened at PLX last week (0415-0419)?
Weekly Report · 04/22 11:31
Weekly Report: what happened at PLX last week (0408-0412)?
Weekly Report · 04/15 11:22
Weekly Report: what happened at PLX last week (0401-0405)?
Weekly Report · 04/08 11:27
Weekly Report: what happened at PLX last week (0325-0329)?
Weekly Report · 04/01 11:24
Weekly Report: what happened at PLX last week (0318-0322)?
Weekly Report · 03/25 11:27
More
Webull provides a variety of real-time PLX stock news. You can receive the latest news about Protalix Biother through multiple platforms. This information may help you make smarter investment decisions.
About PLX
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.